Effect of high-dose antimicrobials on biofilm growth of Achromobacter species isolated from cystic fibrosis patients

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 1, 2016, Pages 650-652

  Tom, Sean K ^a   Yau, Yvonne C W ^a   Beaudoin, Trevor ^a   LiPuma, John J ^b   Waters, Valerie ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; COLISTIN; LEVOFLOXACIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ACHROMOBACTER DENITRIFICANS; ACHROMOBACTER DOLENS; ACHROMOBACTER INSOLITUS; ACHROMOBACTER RUHLANDII; ACHROMOBACTER XYLOSOXIDANS; AEROSOL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BIOFILM; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYSTIC FIBROSIS; IC50; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; ACHROMOBACTER; COMPLICATION; DRUG EFFECTS; GRAM NEGATIVE INFECTION; GROWTH, DEVELOPMENT AND AGING; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PHYSIOLOGY; PLANKTON;

ACHROMOBACTER; AMIKACIN; ANTI-BACTERIAL AGENTS; AZTREONAM; BIOFILMS; COLISTIN; CYSTIC FIBROSIS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; LEVOFLOXACIN; MICROBIAL SENSITIVITY TESTS; PLANKTON; TOBRAMYCIN;

EID: 84957894833     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02240-15     Document Type: Article

References (16)

1. Emerson J, McNamara S, Buccat AM, Worrell K, Burns JL. 2010. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr Pulmonol 45:363-370. http://dx.doi.org/10.1002/ppul.21198.
2. De Baets F, Schelstraete P, Van Daele S, Haerynck F, Vaneechoutte M. 2007. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J Cyst Fibros 6:75-78. http://dx.doi.org/10.1016/j.jcf.2006.05.011.
3. Rønne Hansen C, Pressler T, Høiby N, Gormsen M. 2006. Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients; a retrospective case control study. J Cyst Fibros 5:245-251. http://dx.doi.org/10.1016/j.jcf.2006.04.002.
4. Mensah K, Philippon A, Richard C, Nevot P. 1990. Susceptibility of Alcaligenes denitrificans subspecies xylosoxydans to beta-lactam antibiotics. Eur J Clin Microbiol Infect Dis 9:405-409. http://dx.doi.org/10.1007/BF01979470.
5. Jakobsen TH, Hansen MA, Jensen PØ, Hansen L, Riber L, Cockburn A, Kolpen M, Rønne Hansen C, Ridderberg W, Eickhardt S, Hansen M, Kerpedjiev P, Alhede M, Qvortrup K, Burmølle M, Moser C, Kuhl M, Ciofu O, Givskov M, Sørensen SJ, Høiby N, Bjarnsholt T. 2013. Complete genome sequence of the cystic fibrosis pathogen Achromobacter xylosoxidans NH44784-1996 complies with important pathogenic phenotypes. PLoS One 8:e68484. http://dx.doi.org/10.1371/journal.pone.0068484.
6. Ridderberg W, Nielsen SM, Nørskov-Lauritsen N. 2015. Genetic adaptation of Achromobacter sp. during persistence in the lungs of cystic fibrosis patients. PLoS One 10:e0136790. http://dx.doi.org/10.1371/journal.pone.0136790.
7. Bador J, Amoureux L, Blanc E, Neuwirth C. 2013. Innate aminoglycoside resistance of Achromobacter xylosoxidans is due to AxyXY-OprZ, an RND-type multidrug efflux pump. Antimicrob Agents Chemother 57:603-605. http://dx.doi.org/10.1128/AAC.01243-12.
8. Clinical and Laboratories Standards Institute. 2012. Performance standards for 303 antimicrobial susceptibility testing; 22nd informational supplement. CLSI document M100-S22. Clinical and Laboratories Standards Institute, Wayne, PA.
9. Ratjen A, Yau Y, Wettlaufer J, Matukas L, Zlosnik JE, Speert DP, LiPuma JJ, Tullis E, Waters V. 2015. In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients. Antimicrob Agents Chemother 59:711-713. http://dx.doi.org/10.1128/AAC.04123-14.
10. Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, Ranganathan SC, Waters VJ, Ratjen FA. 2014. Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, Gram-negative bacteria, and multiple infections. Ann Am Thorac Soc 11:1120-1129. http://dx.doi.org/10.1513/AnnalsATS.201402-050AS.
11. Spilker T, Vandamme P, Lipuma JJ. 2013. Identification and distribution of Achromobacter species in cystic fibrosis. J Cyst Fibros 12:298-301. http://dx.doi.org/10.1016/j.jcf.2012.10.002.
12. Vandamme P, Moore ER, Cnockaert M, Peeters C, Svensson-Stadler L, Houf K, Spilker T, LiPuma JJ. 2013. Classification of Achromobacter genogroups 2, 5, 7 and 14 as Achromobacter insuavis sp. nov., Achromobacter aegrifaciens sp. nov., Achromobacter anxifer sp. nov. and Achromobacter dolens sp. nov., respectively. Syst Appl Microbiol 36:474-482. http://dx.doi.org/10.1016/j.syapm.2013.06.005.
13. Biswas S, Dubus JC, Reynaud-Gaubert M, Stremler N, Rolain JM. 2013. Evaluation of colistin susceptibility in multidrug-resistant clinical isolates from cystic fibrosis, France. Eur J Clin Microbiol Infect Dis 32:1461-1464. http://dx.doi.org/10.1007/s10096-013-1898-5.
14. Lambiase A, Catania MR, Del Pezzo M, Rossano F, Terlizzi V, Sepe A, Raia V. 2011. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 30:973-980. http://dx.doi.org/10.1007/s10096-011-1182-5.
15. Trancassini M, Iebba V, Citera N, Tuccio V, Magni A, Varesi P, De Biase RV, Totino V, Santangelo F, Gagliardi A, Schippa S. 2014. Outbreak of Achromobacter xylosoxidans in an Italian cystic fibrosis center: genome variability, biofilm production, antibiotic resistance, and motility in isolated strains. Front Microbiol 5:138. http://dx.doi.org/10.3389/fmicb.2014.00138.
16. Wu K, Yau YC, Matukas L, Waters V. 2013. Biofilm compared to conventional antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from cystic fibrosis patients. Antimicrob Agents Chemother 57:1546-1548. http://dx.doi.org/10.1128/AAC.02215-12.